衛(wei)材(cai)在華企(qi)業隸屬(shu)于(yu)衛(wei)材(cai)株式(shi)會社,衛(wei)材(cai)株式(shi)會社是一(yi)家(jia)以研究開發醫藥(yao)產品(pin)為主的跨國公司,總(zong)部設在日本東京。
衛(wei)(wei)(wei)(wei)(wei)(wei)材中(zhong)國(guo)自上世紀90年(nian)(nian)代初進入中(zhong)國(guo)市場以來順利發(fa)展壯大。自1991年(nian)(nian)先(xian)后成(cheng)(cheng)(cheng)立(li)(li)沈陽衛(wei)(wei)(wei)(wei)(wei)(wei)材制藥(yao)(yao)有限(xian)(xian)(xian)(xian)(xian)(xian)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)和(he)衛(wei)(wei)(wei)(wei)(wei)(wei)材(蘇州(zhou))制藥(yao)(yao)有限(xian)(xian)(xian)(xian)(xian)(xian)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si),并于2002年(nian)(nian)正式(shi)更名為衛(wei)(wei)(wei)(wei)(wei)(wei)材(中(zhong)國(guo))藥(yao)(yao)業(ye)(ye)有限(xian)(xian)(xian)(xian)(xian)(xian)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)。伴隨著中(zhong)國(guo)業(ye)(ye)務(wu)(wu)的(de)發(fa)展,于2010年(nian)(nian)成(cheng)(cheng)(cheng)立(li)(li)衛(wei)(wei)(wei)(wei)(wei)(wei)材(蘇州(zhou))貿易有限(xian)(xian)(xian)(xian)(xian)(xian)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si),于2014年(nian)(nian)成(cheng)(cheng)(cheng)立(li)(li)衛(wei)(wei)(wei)(wei)(wei)(wei)材(中(zhong)國(guo))投資有限(xian)(xian)(xian)(xian)(xian)(xian)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si),并于2015年(nian)(nian)通(tong)過全額收購本地仿制藥(yao)(yao)企(qi)業(ye)(ye)正式(shi)成(cheng)(cheng)(cheng)立(li)(li)衛(wei)(wei)(wei)(wei)(wei)(wei)材(遼寧(ning))制藥(yao)(yao)有限(xian)(xian)(xian)(xian)(xian)(xian)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)。至此,形成(cheng)(cheng)(cheng)了以衛(wei)(wei)(wei)(wei)(wei)(wei)材(中(zhong)國(guo))投資有限(xian)(xian)(xian)(xian)(xian)(xian)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)為資控管理,以衛(wei)(wei)(wei)(wei)(wei)(wei)材(中(zhong)國(guo))藥(yao)(yao)業(ye)(ye)有限(xian)(xian)(xian)(xian)(xian)(xian)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)、衛(wei)(wei)(wei)(wei)(wei)(wei)材(遼寧(ning))制藥(yao)(yao)有限(xian)(xian)(xian)(xian)(xian)(xian)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)、衛(wei)(wei)(wei)(wei)(wei)(wei)材(蘇州(zhou))貿易有限(xian)(xian)(xian)(xian)(xian)(xian)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)為業(ye)(ye)務(wu)(wu)支撐的(de)發(fa)展模式(shi)。為適應中(zhong)國(guo)業(ye)(ye)務(wu)(wu)的(de)迅速發(fa)展,2014年(nian)(nian)11月(yue)衛(wei)(wei)(wei)(wei)(wei)(wei)材(中(zhong)國(guo))藥(yao)(yao)業(ye)(ye)有限(xian)(xian)(xian)(xian)(xian)(xian)公(gong)(gong)(gong)(gong)(gong)(gong)(gong)(gong)司(si)(si)注射劑(ji)工廠竣工, 2017年(nian)(nian)11月(yue)新固體制劑(ji)廠房落成(cheng)(cheng)(cheng),衛(wei)(wei)(wei)(wei)(wei)(wei)材中(zhong)國(guo)的(de)產能得(de)到迅速提(ti)升。
目前,總注冊資本10,854萬(wan)美金。已形成(cheng)以(yi)神經科學領(ling)域(yu)、腫瘤(特藥)領(ling)域(yu)、消(xiao)化肝病領(ling)域(yu)為主要領(ling)域(yu),拓展仿制藥領(ling)域(yu),多達數十種藥品在中國銷售的(de)發(fa)展規(gui)模。
未(wei)來,蘇州工廠除滿足(zu)中國患者(zhe)臨床用藥的(de)需(xu)求(qiu)外(wai),將向亞洲(zhou)其它國家和地區同樣提供高品(pin)質滿足(zu)患者(zhe)需(xu)求(qiu)的(de)產品(pin)。